10x Genomics (TXG) Misses Q1 EPS by 10c; Offers FY23 Revenue Guidance

10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.44), $0.10 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $134.3 million versus the consensus estimate of $129.24 million.

GUIDANCE:

10x Genomics sees FY2023 revenue of $590-610 million, versus the consensus of $593.2 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits